Single-arm clinical study of nituzumab concurrent chemoradiotherapy for EGFR-positive locally advanced head and neck squamous cell carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049720

Enrollment

Unknown

Registered

2021-08-08

Start date

2021-09-08

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of the head and neck

Interventions

experimental group :Nituzumab concurrent chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathological squamous cell carcinoma stage III/IV head and neck cancer; 2. Aged 18 to 70 years; 3. Stage III-IV head and neck squamous cell carcinoma (except nasopharyngeal carcinoma) confirmed by histopathology or cytology, with positive EGFR expression.

Exclusion criteria

Exclusion criteria: 1. Participated in other interventional clinical trials within 30 days of screening; 2. Patients with distant metastasis; 3. Known infection with HV virus or active viral hepatitis; 4. Those who are allergic to the use of this program or are allergic to other ingredients; 5. Patients who are deemed unsuitable by the investigator to participate in this study.

Design outcomes

Primary

Measure	Time frame
2 year overall survival (OS) rate;2 year progression-free survival (PFS) rate;Objective tumor response rate (ORR);Median overall survival (OS);Median progression-free survival (PFS);living quality;	—

Countries

China

Contacts

Public ContactZhong Zhenbin

Harbin Medical University Affiliated Tumor Hospital

15846064167@163.com+86 18646376673

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026